Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The industry rank for Dabomb Protein Biotech's 9-Day RSI or its related term are showing as below:
ROCO:6578's 9-Day RSI is ranked worse than 55.66% of 2111
companies
in the Consumer Packaged Goods industry
Industry Median: 48.75
vs ROCO:6578: 50.80
Dabomb Protein Biotech (ROCO:6578) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Dabomb Protein Biotech 9-Day RSI Related Terms
ROCO:6578 vs KHC, GIS: 9-Day RSI Comparison
For the Packaged Foods subindustry, Dabomb Protein Biotech's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dabomb Protein Biotech 9-Day RSI vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Dabomb Protein Biotech's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Dabomb Protein Biotech's 9-Day RSI falls into.
Dabomb Protein Biotech (ROCO:6578) 9-Day RSI Calculation
The formula for calculating RSI is:
RSI
=
100
–
[ 100
/
( 1 + Average Gain
/
Average Loss )]
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dabomb Protein Biotech (ROCO:6578) has a 9-Day RSI of 50.80 as of Jul. 28, 2026. According to the industry distribution chart, Dabomb Protein Biotech ranks #1175 out of 2111 companies in the Consumer Packaged Goods industry, placing it in the top 55.7%.
Is Dabomb Protein Biotech's 9-Day RSI too high?
Dabomb Protein Biotech's current 9-Day RSI is 50.80. The Consumer Packaged Goods industry median 9-Day RSI is 48.75. Dabomb Protein Biotech's value of 50.80 is 4.2% above this industry median. Based on the distribution chart, Dabomb Protein Biotech ranks #1175 out of 2111 companies in the Consumer Packaged Goods industry, which is below the industry midpoint. Overall, Dabomb Protein Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's 9-Day RSI compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, Dabomb Protein Biotech ranks #1175 out of 2111 companies for 9-Day RSI. This places Dabomb Protein Biotech in the lower half of its industry. The industry median 9-Day RSI is 48.75. Dabomb Protein Biotech's value of 50.80 is 4.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Consumer Packaged Goods company?
The median 9-Day RSI among Consumer Packaged Goods companies is 48.75, based on 2,111 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dabomb Protein Biotech's current 9-Day RSI of 50.80 is 4.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Consumer Packaged Goods industry, the median 9-Day RSI is 48.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dabomb Protein Biotech's current 9-Day RSI is 50.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.40, compared to a current price of NT$16.35 — trading 13.5% above its estimated fair value. The current 9-Day RSI is 50.80 and 4.2% above the Consumer Packaged Goods industry median of 48.75. Dabomb Protein Biotech's overall GF Score™ is 58/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current 9-Day RSI is 50.80 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?
Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued.
The current stock price of NT$16.35 is trading 13.5% above its estimated GF Value™ of NT$14.40.
GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.
Key valuation signals for ROCO:6578:
9-Day RSI: 50.80
GF Value™: NT$14.40 vs. price of NT$16.35 (13.5% above fair value)
Industry Position: 4.2% above the Consumer Packaged Goods median (#1175 of 2111)
No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
58GF Score
Get the complete analysis for ROCO:6578
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6578 has been successfully added to your 
